A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.

Published on Feb 14, 2017in International Journal of Molecular Sciences4.556
· DOI :10.3390/IJMS18020401
Anna M. Serwotka-Suszczak2
Estimated H-index: 2
(UWr: University of Wrocław),
Alicja M. Sochaj-Gregorczyk3
Estimated H-index: 3
(UWr: University of Wrocław)
+ 3 AuthorsJacek Otlewski44
Estimated H-index: 44
(UWr: University of Wrocław)
Antibody-drug conjugates (ADCs) have recently emerged as efficient and selective cancer treatment therapeutics. Currently, alternative forms of drug carriers that can replace monoclonal antibodies are under intensive investigation. Here, a cytotoxic conjugate of an anti-HER2 (Human Epidermal Growth Factor Receptor 2) diaffibody with monomethyl-auristatin E (MMAE) is proposed as a potential anticancer therapeutic. The anti-HER2 diaffibody was based on the ZHER2:4 affibody amino acid sequence. The anti-HER2 diaffibody has been expressed as a His-tagged protein in E. coli and purified by Ni-nitrilotriacetyl (Ni-NTA) agarose chromatography. The molecule was properly folded, and the high affinity and specificity of its interaction with HER2 was confirmed by surface plasmon resonance (SPR) and flow cytometry, respectively. The (ZHER2:4)2DCS-MMAE conjugate was obtained by coupling the maleimide group linked with MMAE to cysteines, which were introduced in a drug conjugation sequence (DCS). Cytotoxicity of the conjugate was evaluated using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide MTT assay and the xCELLigence Real-Time Cell Analyzer. Our experiments demonstrated that the conjugate delivered auristatin E specifically to HER2-positive tumor cells, which finally led to their death. These results indicate that the cytotoxic diaffibody conjugate is a highly potent molecule for the treatment of various types of cancer overexpressing HER2 receptors.
📖 Papers frequently viewed together
21 Citations
9 Citations
15 Citations
#1Alicja M. Sochaj-Gregorczyk (UWr: University of Wrocław)H-Index: 3
Last. Jacek OtlewskiH-Index: 44
view all 3 authors...
Abstract Targeted therapy is a new type of cancer treatment that most often uses biologically active drugs attached to a monoclonal antibody. This so called antibody-drug conjugate strategy allows the use of highly toxic substances that target tumor cells specifically, leaving healthy tissues largely unaffected. Over the last few years, antibody-drug conjugates have become a powerful tool in cancer treatment. We developed and characterized a novel cytotoxic conjugate against HER2 tumors in which...
15 CitationsSource
#1Sujatha P. Koduvayur (UIC: University of Illinois at Chicago)H-Index: 4
#2Ying Su (UIC: University of Illinois at Chicago)H-Index: 7
Last. Arnon Lavie (UIC: University of Illinois at Chicago)H-Index: 5
view all 4 authors...
Cytotoxic drugs, such as nucleoside analogs and toxins, commonly suffer from off-target effects. One approach to mitigate this problem is to deliver the cytotoxic drug selectively to the intended site. While for toxins this can be achieved by conjugating the cell-killing moiety to a targeting moiety, it is not an option for nucleoside analogs, which rely on intracellular enzymes to convert them to their active triphosphorylated form. To overcome this limitation, and achieve site-targeted activat...
4 CitationsSource
#1Anish ThomasH-Index: 36
#2Beverly A TeicherH-Index: 1
Last. Raffit HassanH-Index: 58
view all 3 authors...
Summary Antibody–drug conjugates are monoclonal antibodies conjugated to cytotoxic agents. They use antibodies that are specific to tumour cell-surface proteins and, thus, have tumour specificity and potency not achievable with traditional drugs. Design of effective antibody–drug conjugates for cancer therapy requires selection of an appropriate target, a monoclonal antibody against the target, potent cytotoxic effector molecules, and conjugation of the monoclonal antibody to cytotoxic agents. S...
176 CitationsSource
#1Jens Nørkær Sørensen (Uppsala University)H-Index: 66
#2Irina Velikyan (Uppsala University)H-Index: 23
Last. Henrik LindmanH-Index: 25
view all 12 authors...
PURPOSE: Positron Emission Tomography (PET) imaging of HER2 expression could potentially be used to select patients for HER2-targed therapy, predict response based on uptake and be used for monitor ...
102 CitationsSource
#1Hadis Honarvar (Uppsala University)H-Index: 17
#2Kristina Westerlund (KTH: Royal Institute of Technology)H-Index: 7
Last. Amelie Eriksson Karlström (KTH: Royal Institute of Technology)H-Index: 28
view all 7 authors...
Affibody molecules are small (7 kDa), non-immunoglobulin scaffold proteins with a potential as targeting agents for radionuclide imaging of cancer. However, high renal re-absorption of Affibody molecules prevents their use for radionuclide therapy with residualizing radiometals. We hypothesized that the use of Affibody-based peptide nucleic acid (PNA)-mediated pretargeting would enable higher accumulation of radiometals in tumors than in kidneys. To test this hypothesis, we designed an Affibody-...
38 CitationsSource
#1Alicja M. Sochaj (UWr: University of Wrocław)H-Index: 1
#2Karolina Świderska (UWr: University of Wrocław)H-Index: 2
Last. Jacek Otlewski (UWr: University of Wrocław)H-Index: 44
view all 3 authors...
Abstract Development of efficient and safe cancer therapy is one of the major challenges of the modern medicine. Over the last few years antibody–drug conjugates (ADCs) have become a powerful tool in cancer treatment with two of them, Adcetris® (brentuximab vedotin) and Kadcyla® (ado-trastuzumab emtansine), having recently been approved by the Food and Drug Administration (FDA). Essentially, an ADC is a bioconjugate that comprises a monoclonal antibody that specifically binds tumor surface antig...
96 CitationsSource
#1Hao Liu (KTH: Royal Institute of Technology)H-Index: 4
#1Hao Liu (KTH: Royal Institute of Technology)H-Index: 21
Last. Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
view all 5 authors...
Development of cancer treatment regimens including immunotoxins is partly hampered by their immunogenicity. Recently, deimmunized versions of toxins have been described, potentially being better suited for translation to the clinic. In this study, a recombinant tripartite fusion toxin consisting of a deimmunized version of exotoxin A from Pseudomonas aeruginosa (PE38) genetically fused to an affibody molecule specifically interacting with the human epidermal growth factor receptor 2 (HER2), and ...
16 CitationsSource
Conventional cancer chemotherapy heavily relies on the use of cytotoxic agents, which typically do not preferentially localize at the tumor site and cause toxicity to normal organs, preventing dose escalation to therapeutically active regimens. In principle, antibodies and other ligands could be used for the selective pharmacodelivery of cytotoxic agents to the neoplastic mass. For many years, the availability of ligands, capable of selective internalization into tumor cells, has been considered...
82 CitationsSource
#1Jingmian Zhang (Hebei Medical University)H-Index: 4
#2Xinming Zhao (Hebei Medical University)H-Index: 3
Last. Xiuchun Ren (Hebei Medical University)H-Index: 2
view all 7 authors...
Abstract Introduction Patients with human epidermal growth factor receptor 2 (HER2)-positive cancer are candidates for treatment with the anti-HER2 antibody trastuzumab. How to systemically assess tumor HER2 expression and identifying appropriate use of anti-HER2 therapies by noninvasive imaging in vivo is an urgent issue. The purpose of this study was to evaluate SPECT imaging of 99m Tc-Gly-(D)Ala-Gly-Gly-Z HER2:342 ( 99m Tc-peptide-Z HER2:342 ) for monitoring therapeutic response to trastuzuma...
9 CitationsSource
#1Haleh Saber (CDER: Center for Drug Evaluation and Research)H-Index: 14
#2John K. Leighton (CDER: Center for Drug Evaluation and Research)H-Index: 11
Abstract Antibody-drug conjugates (ADCs) are complex molecules composed of monoclonal antibodies conjugated to potent cytotoxic agents through chemical linkers. Because of this complexity, sponsors have used different approaches for the design of nonclinical studies to support the safety evaluation of ADCs and first-in-human (FIH) dose selection. We analyzed this data with the goal of describing the relationship between nonclinical study results and Phase 1 study outcomes. We summarized the foll...
82 CitationsSource
Cited By10
#1Xi Xi (JLU: Jilin University)H-Index: 1
#2Weihan Sun (JLU: Jilin University)
Last. Fei Sun (JLU: Jilin University)H-Index: 7
view all 6 authors...
Abstract Anti-EGFR nanobodies have been successfully applied as antitumor moieties in the photodynamic therapy and drug delivery systems. But the yields of nanobodies were still limited due to the volumetric capacity of the periplasmic compartments and inclusion bodies of Escherichia coli. A comparative study of Pichia pastoris and Escherichia coli was done through characterizing their products. Nanobody 7D12 and 7D12-9G8 were successfully expressed in Pichia pastoris with 6 to 13.6-fold higher ...
#1Haozhong DingH-Index: 3
#2Tianqi XuH-Index: 2
Last. Anzhelika VorobyevaH-Index: 10
view all 8 authors...
Affibody molecules hold great promise as carriers of cytotoxic drugs for cancer therapy due to their typically high affinity, easy production, and inherent control of the drug molecules' loading and spatial arrangement. Here, the impact of increasing the drug load from one to three on the properties of an affibody drug conjugate targeting the human epidermal growth factor receptor 2 (HER2) was investigated. The affibody carrier was recombinantly expressed as a fusion to an albumin-binding domain...
#1Mahshid Moballegh-Nasery (KMU: Kerman Medical University)H-Index: 1
#2Ali Mandegary (KMU: Kerman Medical University)H-Index: 17
Last. Mohadeseh Mohammadi (Kharazmi University)H-Index: 1
view all 7 authors...
Curcumin is known as an effective anticancer herbal medicine but unfortunately, its bioavailability is poor which necessitate efforts for developing more efficient and specific delivery systems. Human epidermal growth factor receptor 2 (HER 2) due to its overexpression in various types of cancers, is demonstrated to be a good candidate as a target for anticancer therapy. In this study, cytotoxicity of curcumin encapsulated in ZHER2:342 Affibody-decorated liposome was investigated against SKBR3 a...
3 CitationsSource
#1Zachary R. Crook (Fred Hutchinson Cancer Research Center)H-Index: 6
#2Natalie NairnH-Index: 2
Last. James M. Olson (Fred Hutchinson Cancer Research Center)H-Index: 71
view all 3 authors...
Miniproteins are a diverse group of protein scaffolds characterized by small (1–10 kDa) size, stability, and versatility in drug-like roles. Coming largely from native sources, they have been widely adopted into drug development pipelines. While their structures and capabilities are diverse, the approaches to their utilization share more similarities with each other than with more widely used modalities (e.g., antibodies or small molecules). In this review, we highlight recent advances in minipr...
6 CitationsSource
It has been brought to our attention that the affiliation of Dr. Jerzy Pieczykolan at the time when he was responsible for the work described in the paper [...]
#1Mohamed Altai (Uppsala University)H-Index: 19
#2Hao Liu (KTH: Royal Institute of Technology)H-Index: 4
Last. Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
view all 8 authors...
Abstract Patients with HER2-positive tumors often suffer resistance to therapy, warranting development of novel treatment modalities. Affibody molecules are small affinity proteins which can be engineered to bind to desired targets. They have in recent years been found to allow precise targeting of cancer specific molecular signatures such as the HER2 receptor. In this study, we have investigated the potential of an affibody molecule targeting HER2, ZHER2:2891, conjugated with the cytotoxic mayt...
17 CitationsSource
#1Dasa Lipovsek (BMS: Bristol-Myers Squibb)H-Index: 8
#2Irvith M. Carvajal (BMS: Bristol-Myers Squibb)H-Index: 8
Last. James W. Bryson (BMS: Bristol-Myers Squibb)H-Index: 7
view all 23 authors...
: Tumor-specific delivery of cytotoxic agents remains a challenge in cancer therapy. Antibody-drug conjugates (ADC) deliver their payloads to tumor cells that overexpress specific tumor-associated antigens-but the multi-day half-life of ADC leads to high exposure even of normal, antigen-free, tissues and thus contributes to dose-limiting toxicity. Here, we present Adnectin-drug conjugates, an alternative platform for tumor-specific delivery of cytotoxic payloads. Due to their small size (10 kDa)...
10 CitationsSource
#1Alicja M. Sochaj-Gregorczyk (UWr: University of Wrocław)H-Index: 3
#2Patryk Ludzia (UWr: University of Wrocław)H-Index: 3
Last. Jacek Otlewski (UWr: University of Wrocław)H-Index: 44
view all 6 authors...
In our previous work we demonstrated that a small protein called affibody can be used for a cytotoxic conjugate development. The anti-HER2 affibody was armed with one moiety of a highly potent auristatin E and specifically killed HER2-positive cancer cells with a nanomolar IC50. The aim of this study was to improve the anti-HER2 affibody conjugate by increasing its size and the number of conjugated auristatin molecules. The affibody was fused to the Fc fragment of IgG1 resulting in a dimeric con...
9 CitationsSource
#1Stefan Ståhl (KTH: Royal Institute of Technology)H-Index: 66
#2Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
Last. John Löfblom (KTH: Royal Institute of Technology)H-Index: 24
view all 6 authors...
Affibody molecules are small (6.5-kDa) affinity proteins based on a three-helix bundle domain framework. Since their introduction 20 years ago as an alternative to antibodies for biotechnological applications, the first therapeutic affibody molecules have now entered clinical development and more than 400 studies have been published in which affibody molecules have been developed and used in a variety of contexts. In this review, we focus primarily on efforts over the past 5 years to explore the...
98 CitationsSource
#1Feifei An (Cornell University)H-Index: 17
#2Harikrishna Kommidi (Cornell University)H-Index: 8
Last. Richard Ting (Cornell University)H-Index: 18
view all 4 authors...
The novel synthesis of a dual-modality, pentamethine cyanine (Cy5) fluorescent, 18F positron emission tomography (PET) imaging probe is reported. The probe shows a large extinction coefficient and large quantum yield in the biologically transparent, near-infrared window (650–900 nm) for in vivo fluorescent imaging. This fluorophore bears the isotope, 18F, giving a 18F-PET/near-infrared fluorescent (NIRF), bi-modal imaging probe, that combines the long-term stability of NIRF and the unlimited pen...
11 CitationsSource